Keynote review: phosphodiesterase-4 as a therapeutic target.

By M. Houslay, P. Schafer, Kam Y. J. Zhang. Drug Discovery Today, 2005

625 citations recorded by the source corpus.

Subfields: Molecular Biology, Organic Chemistry, Pharmacology

View Paper: https://www.semanticscholar.org/paper/8b80ed6cc88ff1187638a0e3a25ab662873f7efd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. C. Griffiths
2. K. Papp
3. C. Leonardi
4. K. Reich
5. R. Langley
6. N. Korman
7. K. Gordon
8. R. Stevens

Citations in the corpus

• Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). (2015, background): “Cyclic adenosine monophosphate, a key modulator of immune cell responses, is predominantly regulated by phosphodiesterase 4 (PDE4).(1) Apremilast, an oral PDE4 inhibitor, works intracellularly to regulate inflammatory mediators, including pathways relevant to the pathogenesis of psoriasis.”